Malec L, Carcao M, Mathias M, Kragh N, Dumont J, Willemze A, Bystricka L, Wilson A, DiBenedetti D. Experiences with efanesoctocog alfa: exit interviews with caregivers of previously treated patients with hemophilia a from the XTEND-Kids phase 3 clinical trial. Presented at the 65th ASH Annual Meeting & Exposition 2023; December 10, 2023. San Diego, CA.
Escobar MA, Fan QA, Mokdad AG, Tarantino MD, Burgess B, Hawe E, Fernandez M, Bullano M. Clinical outcomes of noninhibitor patients with hemophilia a switching from prophylaxis with factor VIII to emicizumab: a meta-analysis of real-world evidence studies. Presented at the 65th ASH Annual Meeting & Exposition 2023; December 9, 2023. San Diego, CA.
Ho M, Gonzalez JM, Mansfield C, Wilson L. Three preference studies sponsored by FDA CBER to inform benefit-risk assessment for biologics. Presented at the Virtual ISPOR 2021 Conference; May 20, 2021.
Gonzalez Sepulveda JM, Irony T, Mansfield C, Wilson L. Stated preferences to inform benefit-risk assessment for biologics-three FDA-sponsored studies. Presented at the 2020 ISPOR Virtual Conference; May 18, 2020.
DiBenedetti DB, Coles TM, Sharma T, Pericleous L. Patients' and caregivers' perspectives on stability of factor viii products for hemophilia a: a web-based study in the United States and Canada. Presented at the 65th Annual International Meeting, National Hemophilia Foundation; October 2013. Anaheim, CA.
Harrison CN, Kiladjian J-J, Al-Ali H-K, Gisslinger H, Knoops L, Waltzman RJ, Copley-Merriman K. Health-related quality of life and symptoms in myelofibrosis patients treated with ruxolitinib versus best available therapy. Presented at the European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes; May 2012.
Arana A, Cid Ruzafa J, Rueda de Castro AM, Warner BA, O'Sullivan D. Evaluation of the clozaril® patient monitoring service (CPMS) in the prevention of clozaril/leponex-induced white-blood-celltoxicity. Presented at the 18th International Conference on Pharmacoepidemiology; August 2002.
Anthony MS, Clarkson TB. Association between plasma isoflavone and plasma lipoprotein concentrations. Presented at the Symposium on Phytoestrogen Research Methods; September 1997. Tucson, AZ.